ANGO vs. ARAY, SRDX, CTSO, OFIX, SGHT, RCEL, UTMD, LUNG, INO, and CERS
Should you be buying AngioDynamics stock or one of its competitors? The main competitors of AngioDynamics include Accuray (ARAY), Surmodics (SRDX), Cytosorbents (CTSO), Orthofix Medical (OFIX), Sight Sciences (SGHT), AVITA Medical (RCEL), Utah Medical Products (UTMD), Pulmonx (LUNG), Inovio Pharmaceuticals (INO), and Cerus (CERS). These companies are all part of the "surgical & medical instruments" industry.
Accuray (NASDAQ:ARAY) and AngioDynamics (NASDAQ:ANGO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.
Accuray presently has a consensus price target of $8.25, suggesting a potential upside of 275.00%. AngioDynamics has a consensus price target of $14.25, suggesting a potential upside of 142.76%. Given AngioDynamics' higher probable upside, equities research analysts clearly believe Accuray is more favorable than AngioDynamics.
Accuray has a beta of 1.44, meaning that its stock price is 44% more volatile than the S&P 500. Comparatively, AngioDynamics has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500.
AngioDynamics received 30 more outperform votes than Accuray when rated by MarketBeat users. However, 65.67% of users gave Accuray an outperform vote while only 60.67% of users gave AngioDynamics an outperform vote.
64.1% of Accuray shares are held by institutional investors. Comparatively, 89.4% of AngioDynamics shares are held by institutional investors. 3.8% of Accuray shares are held by company insiders. Comparatively, 5.1% of AngioDynamics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Accuray had 2 more articles in the media than AngioDynamics. MarketBeat recorded 3 mentions for Accuray and 1 mentions for AngioDynamics. AngioDynamics' average media sentiment score of 0.63 beat Accuray's score of 0.00 indicating that Accuray is being referred to more favorably in the media.
Accuray has a net margin of -3.25% compared to Accuray's net margin of -60.21%. Accuray's return on equity of -3.48% beat AngioDynamics' return on equity.
Accuray has higher revenue and earnings than AngioDynamics. Accuray is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks.
Summary
Accuray beats AngioDynamics on 9 of the 17 factors compared between the two stocks.
Get AngioDynamics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANGO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AngioDynamics Competitors List
Related Companies and Tools
